What’s Positive About ‘Triple-Negative’ Breast Cancer?

• Jemal A , SiegelR, WardEet al.: Cancer statistics, 2008.CA Cancer J. Clin.58, 71–96 (2008).
   PubMed Web of Science ®Google Scholar
• Jatoi I , ChenBE, AndersonWF, RosenbergPS: Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.J. Clin. Oncol.25, 1683–1690 (2007).
   PubMed Web of Science ®Google Scholar
• Hurvitz SA , PietrasRJ: Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions.Cancer113, 2385–2397 (2008).
   PubMed Web of Science ®Google Scholar
• Dean-Colomb W , EstevaFJ: Her2-positive breast cancer: herceptin and beyond.Eur. J. Cancer44, 2806–2812 (2008).
   PubMed Web of Science ®Google Scholar
• Nielsen TO , HsuFD, JensenKet al.: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.Clin. Cancer Res.10, 5367–5374 (2004).
   PubMed Web of Science ®Google Scholar
• Carey LA , PerouCM, LivasyCAet al.: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.JAMA295, 2492–2502 (2006).
   PubMed Web of Science ®Google Scholar
• Perou CM , SorlieT, EisenMBet al.: Molecular portraits of human breast tumours.Nature406, 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Sorlie T , PerouCM, TibshiraniRet al.: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.Proc. Natl Acad. Sci. USA98, 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Sotiriou C , NeoSY, McShaneLMet al.: Breast cancer classification and prognosis based on gene expression profiles from a population-based study.Proc. Natl Acad. Sci. USA100, 10393–10398 (2003).
   PubMed Web of Science ®Google Scholar
• Livasy CA , KaracaG, NandaRet al.: Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.Mod. Pathol.19, 264–271 (2006).
   PubMed Web of Science ®Google Scholar
• Rakha EA , El-SayedME, GreenAR, PaishEC, LeeAH, EllisIO: Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression.Histopathology50, 434–438 (2007).
   PubMed Web of Science ®Google Scholar
• Sorlie T , TibshiraniR, ParkerJet al.: Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc. Natl Acad. Sci. USA100, 8418–8423 (2003).
   PubMed Web of Science ®Google Scholar
• Langerod A , ZhaoH, BorganOet al.: TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer.Breast Cancer Res.9, R30 (2007).
   PubMed Web of Science ®Google Scholar
• Reis-Filho JS , MilaneziF, SteeleDet al.: Metaplastic breast carcinomas are basal-like tumours.Histopathology49, 10–21 (2006).
   PubMed Web of Science ®Google Scholar
• Jacquemier J , PadovaniL, RabayrolLet al.: Typical medullary breast carcinomas have a basal/myoepithelial phenotype.J. Pathol.207, 260–268 (2005).
   PubMed Web of Science ®Google Scholar
• Rakha EA , PuttiTC, Abd El-RehimDMet al.: Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.J. Pathol.208, 495–506 (2006).
   PubMed Web of Science ®Google Scholar
• Wetzels RH , HollandR, van HaelstUJ, LaneEB, LeighIM, RamaekersFC: Detection of basement membrane components and basal cell keratin 14 in noninvasive and invasive carcinomas of the breast.Am. J. Pathol.134, 571–579 (1989).
   PubMed Web of Science ®Google Scholar
• Bertucci F , FinettiP, CerveraNet al.: How basal are triple-negative breast cancers?Int. J. Cancer123, 236–240 (2008).
   PubMed Web of Science ®Google Scholar
• Kreike B , van KouwenhoveM, HorlingsHet al.: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.Breast Cancer Res.9, R65 (2007).
   PubMed Web of Science ®Google Scholar
• Cheang MC , VoducD, BajdikCet al.: Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.Clin. Cancer Res.14, 1368–1376 (2008).
   PubMed Web of Science ®Google Scholar
• Rakha EA , ElsheikhSE, AleskandaranyMAet al.: Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.Clin. Cancer Res.15, 2302–2310 (2009).
   PubMed Web of Science ®Google Scholar
• Rakha EA , El-RehimDA, PaishCet al.: Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance.Eur. J. Cancer42, 3149–3156 (2006).
   PubMed Web of Science ®Google Scholar
• Dent R , TrudeauM, PritchardKIet al.: Triple-negative breast cancer: clinical features and patterns of recurrence.Clin. Cancer Res.13, 4429–4434 (2007).
   PubMed Web of Science ®Google Scholar
• Yarden Y , SliwkowskiMX: Untangling the ErbB signalling network.Nat. Rev. Mol. Cell Biol.2, 127–137 (2001).
   PubMed Web of Science ®Google Scholar
• Schlessinger J : Ligand-induced, receptor-mediated dimerization and activation of EGF receptor.Cell110, 669–672 (2002).
   PubMed Web of Science ®Google Scholar
• Johnston JB , NavaratnamS, PitzMWet al.: Targeting the EGFR pathway for cancer therapy.Curr. Med. Chem.13, 3483–3492 (2006).
   PubMed Web of Science ®Google Scholar
• Shepherd FA , Rodrigues PereiraJ, CiuleanuTet al.: Erlotinib in previously treated non-small-cell lung cancer.N. Engl. J. Med.353, 123–132 (2005).
   PubMed Web of Science ®Google Scholar
• Bonner JA , HarariPM, GiraltJet al.: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.N. Engl. J. Med.354, 567–578 (2006).
   PubMed Web of Science ®Google Scholar
• Cunningham D , HumbletY, SienaSet al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.N. Engl. J. Med.351, 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Dennison SK , JacobsSA, WilsonJWet al.: A Phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.Invest. New Drugs25, 545–551 (2007).
   PubMed Web of Science ®Google Scholar
• Smith IE , WalshG, SkeneAet al.: A Phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.J. Clin. Oncol.25, 3816–3822 (2007).
   PubMed Web of Science ®Google Scholar
• Heist RS , ChristianiD: EGFR-targeted therapies in lung cancer: predictors of response and toxicity.Pharmacogenomics10, 59–68 (2009).
   PubMed Web of Science ®Google Scholar
• Allegra CJ , JessupJM, SomerfieldMRet al.: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.J. Clin. Oncol.27, 2091–2096 (2009).
   PubMed Web of Science ®Google Scholar
• Aboud-Pirak E , HurwitzE, PirakME, BellotF, SchlessingerJ, SelaM: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice.J. Natl Cancer Inst.80, 1605–1611 (1988).
   PubMed Web of Science ®Google Scholar
• Oliveras-Ferraros C , Vazquez-MartinA, Lopez-BonetEet al.: Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.Int. J. Oncol.33, 1165–1176 (2008).
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy JWD , VukeljaSJ, McIntyreKet al.: Preliminary results of a randomized Phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer.Breast Cancer Res. Treat.106(Suppl. 1), S32 (2007).
   Google Scholar
• Carey LA , RugoHS, MarcomPKet al.: TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer.J. Clin. Oncol.26 (2008) (Abstract 1009).
   Google Scholar
• Di Leo A , GomezHL, AzizZet al.: Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.J. Clin. Oncol.26, 5544–5552 (2008).
   PubMed Web of Science ®Google Scholar
• Finn RS , PressMF, DeringJet al.: ER, PR, HER2, and EGFR expression and benefit from laptinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in 579 women with HER2 negative or unknown metastatic breast cancer.J. Clin. Oncol.27(24), 3908–3915 (2009).
   PubMed Web of Science ®Google Scholar
• Hanahan D , WeinbergRA: The hallmarks of cancer.Cell100, 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Ferrara N , GerberHP, LeCouterJ: The biology of VEGF and its receptors.Nat. Med.9, 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Foulkes WD , BrunetJS, StefanssonIMet al.: The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.Cancer Res.64, 830–835 (2004).
   PubMed Web of Science ®Google Scholar
• Holash J , WiegandSJ, YancopoulosGD: New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF.Oncogene18, 5356–5362 (1999).
   PubMed Web of Science ®Google Scholar
• Miller KD , BursteinHJ, EliasADet al.: Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC).J. Clin. Oncol.23 (2005) (Abstract 563).
   Google Scholar
• Burstein HJ , EliasAD, RugoHSet al.: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.J. Clin. Oncol.26, 1810–1816 (2008).
   PubMed Web of Science ®Google Scholar
• Gianni L , CardosoF, MarianiGet al.: Exploratory evaluation of a sequential administration of docetaxel and sunitinib in women with advanced breast cancer.Breast Cancer Res. Treat.106(Suppl. 1) S273 (2007).
   PubMedGoogle Scholar
• Miller K , WangM, GralowJet al.: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.N. Engl. J. Med.357, 2666–2676 (2007).
   PubMed Web of Science ®Google Scholar
• Miles D , ChanA, RomieuGet al.: Randomized, double-blind, placebo-controlled, Phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.J. Clin. Oncol.26 (2008) (Abstract LBA1011).
   Google Scholar
• Finn RS : Targeting Src in breast cancer.Ann. Oncol.19, 1379–1386 (2008).
   PubMed Web of Science ®Google Scholar
• Finn RS , DeringJ, GintherCet al.: Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/‘triple-negative’ breast cancer cell lines growing in vitro.Breast Cancer Res Treat.105, 319–326 (2007).
   PubMed Web of Science ®Google Scholar
• Huang F , ReevesK, HanXet al.: Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection.Cancer Res.67, 2226–2238 (2007).
   PubMed Web of Science ®Google Scholar
• Finn RS , BengalaC, IbrahimNet al.: Phase II trial of dasatinib in triple-negative breast cancer: results of study CA 180059. Presented at:San Antonio Breast Cancer Symposium. TX, USA, 10–14 December 2008. (Abstract 3118).
   Google Scholar
• Foulkes WD , StefanssonIM, ChappuisPOet al.: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.J. Natl Cancer Inst.95, 1482–1485 (2003).
   PubMed Web of Science ®Google Scholar
• Turner NC , Reis-FilhoJS, RussellAMet al.: BRCA1 dysfunction in sporadic basal-like breast cancer.Oncogene26, 2126–2132 (2007).
   PubMed Web of Science ®Google Scholar
• Turner NC , Reis-FilhoJS: Basal-like breast cancer and the BRCA1 phenotype.Oncogene25, 5846–5853 (2006).
   PubMed Web of Science ®Google Scholar
• Bryant HE , HelledayT: Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents.Biochem. Soc. Trans.32, 959–961 (2004).
   PubMed Web of Science ®Google Scholar
• Kuzminov A : Single-strand interruptions in replicating chromosomes cause double-strand breaks.Proc. Natl Acad. Sci. USA98, 8241–8246 (2001).
   PubMed Web of Science ®Google Scholar
• Yap TA , BossDS, FongPCet al.: First in human Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers.J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I, 25, S18 (2007).
   Web of Science ®Google Scholar
• Futreal PA , LiuQ, Shattuck-EidensDet al.: BRCA1 mutations in primary breast and ovarian carcinomas.Science266, 120–122 (1994).
   PubMed Web of Science ®Google Scholar
• De Soto JA , DengCX: PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?Int. J. Med. Sci.3, 117–123 (2006).
   PubMedGoogle Scholar
• O’Shaughnessy J , OsborneC, PippenJet al.: Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patinets with metastatic triple-negative breast cancer (TNBC): results of a randomized Phase II trial.J. Clin. Oncol.27, S18 (2009) (Abstract 3).
   Google Scholar
• Heinrich MC , BlankeCD, DrukerBJ, CorlessCL: Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.J. Clin. Oncol.20, 1692–1703 (2002).
   PubMed Web of Science ®Google Scholar
• Simon R , PanussisS, MaurerRet al.: KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations.Clin. Cancer Res.10, 178–183 (2004).
   PubMed Web of Science ®Google Scholar
• Go RS , AdjeiAA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.J. Clin. Oncol.17, 409–422 (1999).
   PubMed Web of Science ®Google Scholar
• Quinn JE , KennedyRD, MullanPBet al.: BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis.Cancer Res.63, 6221–6228 (2003).
   PubMed Web of Science ®Google Scholar
• Rottenberg S , NygrenAO, PajicMet al.: Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer.Proc. Natl Acad. Sci. USA104, 12117–12122 (2007).
   PubMed Web of Science ®Google Scholar
• Chia JW , AngP, SeeHet al.: Triple-negative metastatic/recurrent breast cancer: treatment with paclitaxel/carboplatin combination chemotherapy.Proc. Am. Soc. Clin. Oncol.25 (2007) (Abstract 1086).
   Google Scholar
• Garber JE , RichardsonA, HarrisLNet al.: Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC).Breast Cancer Res Treat.100(Suppl. 1) (2006) (Abstract 3074).
   Google Scholar
• Yap HY , SalemP, HortobagyiGNet al.: Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer.Cancer Treat. Rep.62, 405–408 (1978).
   PubMedGoogle Scholar
• Ostrow S , EgorinM, AisnerJ, BachurN, WiernikPH: High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.Cancer Clin. Trials3, 23–27 (1980).
   PubMedGoogle Scholar
• Hotchkiss KA , AshtonAW, MahmoodR, RussellRG, SparanoJA, SchwartzEL: Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center.Mol. Cancer Ther.1, 1191–1200 (2002).
   PubMed Web of Science ®Google Scholar
• Mabjeesh NJ , EscuinD, LaValleeTMet al.: 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.Cancer Cell3, 363–375 (2003).
   PubMed Web of Science ®Google Scholar
• Lau DH , XueL, YoungLJ, BurkePA, CheungAT: Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer.Cancer Biother. Radiopharm.14, 31–36 (1999).
   PubMed Web of Science ®Google Scholar
• Ettenson DS , GotliebAI: Centrosomes, microtubules, and microfilaments in the reendothelialization and remodeling of double-sided in vitro wounds.Lab. Invest.66, 722–733 (1992).
   PubMed Web of Science ®Google Scholar
• Belotti D , VerganiV, DrudisTet al.: The microtubule-affecting drug paclitaxel has antiangiogenic activity.Clin. Cancer Res.2, 1843–1849 (1996).
   PubMed Web of Science ®Google Scholar
• Klauber N , ParangiS, FlynnE, HamelE, D’AmatoRJ: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.Cancer Res.57, 81–86 (1997).
   PubMed Web of Science ®Google Scholar
• Vacca A , RibattiD, IurlaroMet al.: Docetaxel versus paclitaxel for antiangiogenesis.J. Hematother. Stem Cell Res.11, 103–118 (2002).
   PubMedGoogle Scholar
• Grant DS , WilliamsTL, ZahaczewskyM, DickerAP: Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).Int. J. Cancer104, 121–129 (2003).
   PubMed Web of Science ®Google Scholar
• Jones S , HolmesFA, O’ShaughnessyJet al.: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735.J. Clin. Oncol.27, 1177–1183 (2009).
   PubMed Web of Science ®Google Scholar
• Chang H , SlamonD, PratiRet al.: A Phase II study of neoadjuvant docetaxel/carboplatin, with or without trastuzumab in locally advanced breast cancer: response and cardiotoxicity.J. Clin. Oncol. ASCO Annual Meeting Proceedings 24, S18 (2006) (Abstract 845).
   Google Scholar
• Chang HR , SlamonD, GornbeinJA, ChungD: Preferential pathologic complete response (pCR) by triple-negative (-) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C).J. Clin. Oncol.26 (2008) (Abstract 604).
   Google Scholar
• Roy V , PockajBA, NorthfeltDW, AllredJBet al.: N0338 Phase II trial of docetaxel and carboplatin administered every two weeks as induction therapy for stage II or III breast cancer.J. Clin. Oncol.26(Suppl.) (2008) (Abstract 563).
   PubMedGoogle Scholar
• Hugh J , HansonJ, CheangMCet al.: Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.J. Clin. Oncol.27, 1168–1176 (2009).
   PubMed Web of Science ®Google Scholar
• Perez EA , LerzoG, PivotXet al.: Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.J. Clin. Oncol.25, 3407–3414 (2007).
   PubMed Web of Science ®Google Scholar
• Baselga J , ZambettiM, Llombart-CussacAet al.: Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.J. Clin. Oncol.27, 526–534 (2009).
   PubMed Web of Science ®Google Scholar
• Thomas ES , GomezHL, LiRKet al.: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.J. Clin. Oncol.25, 5210–5217 (2007).
   PubMed Web of Science ®Google Scholar

Website

• Registry of federally and privately supported clinical trials www.clinicaltrials.gov
   Google Scholar